Clinical trial
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or…
NCT00363272 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00363272 |
|---|---|
| Title | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma |
| Official title | A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebral Astrocytoma and 16 more |
| Intervention type | Drug, Other |
| Interventions | ispinesib, laboratory biomarker analysis, pharmacological study |
| Enrollment | 30 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2008 |
| First posted | Aug 15, 2006 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: